SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the “Board”) has appointed Brian J.

圣地亚哥--（商业新闻短讯）--QuidelOrtho Corporation（Nasdaq:QDEL）（“公司”或“QuidelOrtho”）是一家为医疗机构、临床实验室和输血医学设计的创新体外诊断技术的全球供应商，宣布公司董事会（“董事会”）任命BrianJ。

Blaser as President and Chief Executive Officer (“CEO”) effective May 6. In addition to his appointment as President and CEO, Mr. Blaser will join the Board, effective May 15, 2024, when the Board will be expanded from ten to eleven members..

Blaser担任总裁兼首席执行官（“CEO”），自5月6日起生效。除了被任命为总裁和首席执行官外，布拉瑟先生还将于2024年5月15日加入董事会，届时董事会成员将从10名扩大到11名。。

“We are excited to welcome Brian as our new president, CEO and director,” said Kenneth F. Buechler, Ph.D., Chairman of the Board. “Brian brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including seven years of full responsibility for Abbott’s global diagnostics business.

董事会主席KennethF.Buechler博士说：“我们很高兴欢迎Brian担任我们的新任总裁、首席执行官和董事。”。“Brian在体外诊断行业拥有超过25年的高级领导经验，其中包括七年对雅培全球诊断业务的全面负责。

His proven track record of executing transformational strategies to streamline operations and driving revenue growth to dramatically improve profitability makes him an ideal leader to guide QuidelOrtho through its next phase of growth.”.

他在执行转型战略以简化运营和推动收入增长以大幅提高盈利能力方面的良好记录，使他成为指导QuidelOrtho完成下一阶段增长的理想领导者。”。

Mr. Blaser most recently served as Executive Vice President, Diagnostic Products of Abbott Laboratories, where he oversaw the global diagnostics organization, including core laboratory, point of care, rapid diagnostics, and molecular diagnostics businesses. Prior to that role, Mr. Blaser held various strategic, operational, and diagnostic roles at Abbott, as well as previous leadership positions at the Ortho Clinical Diagnostics division of Johnson & Johnson, Eastman Kodak, and General Motors..

布拉瑟先生最近担任雅培实验室诊断产品执行副总裁，负责管理全球诊断组织，包括核心实验室、即时护理、快速诊断和分子诊断业务。在此之前，Blaser先生曾在雅培担任过各种战略、运营和诊断职务，并曾在强生公司、伊士曼柯达公司和通用汽车公司的Ortho Clinical Diagnostics部门担任领导职务。。

“I am honored and excited to join QuidelOrtho as president and CEO during this pivotal point in the Company’s journey. The Company’s commitment to customer service and its dedication to improving healthcare outcomes align closely with my own values,” said Brian J. Blaser, President and CEO, QuidelOrtho.

QuidelOrtho总裁兼首席执行官布莱恩·布拉瑟（BrianJ.Blaser）表示：“在公司历程的关键时刻，我很荣幸和兴奋能加入QuidelOrtho担任总裁兼首席执行官。公司对客户服务的承诺以及对改善医疗保健成果的奉献与我自己的价值观密切相关。”。

“I am eager to collaborate with the QuidelOrtho team to drive innovation and continued growth, while delivering value to customers, shareholders and employees.”.

“我渴望与QuidelOrtho团队合作，推动创新和持续增长，同时为客户、股东和员工提供价值。”。

Mr. Blaser holds an MBA with a concentration in Finance from the Rochester Institute of Technology and a Bachelor of Sciences in Mechanical Engineering Technology from the University of Dayton. He is actively involved in various industry and community organizations, including serving as Advisory Council Chair of the University of Dayton School of Engineering and Chairman of the Board of Trustees for Cristo-Rey St.

Blaser先生拥有罗切斯特理工学院金融专业的MBA学位和代顿大学机械工程技术的理学学士学位。他积极参与各种行业和社区组织，包括担任代顿大学工程学院顾问委员会主席和克里斯托·雷伊·圣的董事会主席。

Martin College Prep..

马丁学院预科。。

“The Board would also like to take this opportunity to thank Michael Iskra, Robert Bujarski and Joseph Busky for their leadership during this transition period. Together, they advanced many critical initiatives while stabilizing a solid foundation for the Company’s continued growth,” Dr. Buechler said..

“董事会还要借此机会感谢迈克尔·伊斯克拉（Michael Iskra）、罗伯特·布贾斯基（Robert Bujarski）和约瑟夫·巴斯基（Joseph Busky）在这一过渡时期的领导。他们共同提出了许多关键举措，同时为公司的持续增长奠定了坚实的基础，”布勒博士说。。

The Company will report its first quarter 2024 financial results on May 8, 2024.

该公司将于2024年5月8日报告其2024年第一季度的财务业绩。

About QuidelOrtho Corporation

关于QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

QuidelOrtho Corporation（纳斯达克股票代码：QDEL）是体外诊断、开发和制造智能解决方案的世界领导者，该解决方案可以将数据转化为理解和行动，每天为更多地方的更多人服务。

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence..

在免疫分析和分子检测、临床化学和输血医学方面提供业界领先的专业知识，在需要时随时随地提供快速、准确和可靠的诊断-从家到医院，从实验室到诊所。这样，患者、临床医生和卫生官员就可以更快地发现趋势，更快地做出反应，并以准确和自信的态度规划未来的进程。。

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects, and a more informed path is illuminated for each of us..

在多年突破性创新的基础上，QuidelOrtho继续与医疗保健连续体和全球各地的客户合作，打造新的诊断前沿。在这里，见解和解决方案无限，专业知识无缝连接，为我们每个人照亮了一条更加明智的道路。。

QuidelOrtho is advancing diagnostics to power a healthier future.

QuidelOrtho正在推进诊断，以推动更健康的未来。

For more information, please visit www.quidelortho.com.

欲了解更多信息，请访问www.quidelortho.com。

Source: QuidelOrtho Corporation

资料来源：QuidelOrtho Corporation